NCT05988112

Brief Summary

our study will be retrospective on breast cancer patients to detect relation between the locoregional recurrence of breast cancer after radiotherapy and the molecular subtypes

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
265

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 4, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 14, 2023

Completed
12 months until next milestone

Study Start

First participant enrolled

August 1, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2025

Completed
Last Updated

July 16, 2024

Status Verified

July 1, 2024

Enrollment Period

11 months

First QC Date

August 4, 2023

Last Update Submit

July 15, 2024

Conditions

Locoregional Recurrence

Outcome Measures

Primary Outcomes (2)

  • Determine Local & regional recurrence according to different molecular subtypes.

    radiologically or with re biopsy

    within 5 years from diagnosis

  • - 5-year free survival

    radiologically

    within 5 years from diagnosis

Secondary Outcomes (1)

  • Metastasis-Free Survival

    within 5 years from diagnosis

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients diagnosed with breast cancer in clinical oncology department , Assuit university hospital

You may qualify if:

  • Age ≥ 18
  • Male or female
  • Histological proven breast cancer (IDC / ILC)
  • with known receptor status
  • Patient did mastectomy or breast conservative surgery +/- lymph node dissection .
  • received radiotherapy
  • on regular follow up

You may not qualify if:

  • Metastatic from the start (stage 4)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Amira Ali Fekry, master

CONTACT

01099824589aliamera825@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

August 4, 2023

First Posted

August 14, 2023

Study Start

August 1, 2024

Primary Completion

July 1, 2025

Study Completion

September 1, 2025

Last Updated

July 16, 2024

Record last verified: 2024-07